Topas Therapeutics Raises €22 Million in Series B Financing
Funds to be used to advance innovative pipeline based on Topas Particle Conjugates technology platform
26-Oct-2020 -
Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform startup leveraging the natural immune tolerance induction capabilities of the liver, today announced the successful closing of a €22 million (~$26 million) Series B financing round. New investors Vesalius BioCapital III ...
celiac disease
pemphigus vulgaris
Series B financing